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A B S T R A C T
Spironolactone form I melts at about 70 degrees lower than form II, which is very unusual for two co-existing
polymorphs. The phase relationships involving this unprecedented case of dimorphism have been investigated by
constructing a topological pressure-temperature phase diagram. The transition from polymorph I to polymorph
II is unambiguously exothermic while it is accompanied with an increase in the specific volume. This indicates
that the dP/dT slope of the I-II equilibrium curve is negative. The convergence of the melting equilibrium lines
at high pressure lead to a topological P-T diagram in which polymorph I possesses a stable phase region at high
pressure. Thus, forms I and II are monotropically related at ordinary pressure and turn to an enantiotropic re-
lationship at high pressure. Given that polymorph I is the densest form, it negates the rule of thumb that the
densest form is also the most stable form at room temperature, similar to the case of paracetamol.
1. Introduction
1.1. The exceptional difference between the melting points of the two
polymorphs of spironolactone
Most crystalline polymorphs of molecular compounds possess melt-
ing points that differ from each other by only a few degrees. Differences
of more than fifty degrees are very rare, as can be inferred from a com-
pilation of 103 sets of polymorphic systems involving “pharmaceuticals
and other molecular compounds” by Burger and Ramberger (Burger and
Ramberger, 1979b) in addition to more recent cases, which have been
compiled in Table 1. In Fig. 1, it is shown that about 56% of these
systems exhibit differences between their melting temperatures smaller
than 10K, and only fifteen cases (≈5%) exhibit differences higher than
40 °C, which on closer scrutiny occurs mainly between the more stable
polymorph and a polymorph ranking fourth or fifth in metastability.
The dimorphic system involving the orthorhombic forms of spirono-
lactone, form I (Dideberg and Dupont, 1972) and form II (Agafonov et
al., 1989), appear to exhibit a difference of more than 70 degrees in
their melting temperatures, making it therefore an exceptionally un-
common case of crystalline polymorphism (Espeau et al., 2007). Form
I melts and recrystallizes into form II in the temperature interval of
373–393K. Form II, however, only melts at 480–483K.
With such a large difference in melting points, it is rather puzzling
why form I appears at all and the question arises whether form I has
a stable domain in the pressure-temperature phase diagram, either at
low temperature or at high pressure. For high-pressure measurements,
a special analyzer developed in-house in the UPC (Barcelona) would
have been a useful tool, however, the melting point of form II falls out-
side of its temperature range and the signals of the other transitions
are too weak to be observed with sufficient precision. Therefore, us-
ing calorimetric and crystallographic data available in the literature and
new experimental results obtained under ordinary pressure⁠1, a topologi-
cal pressure-temperature phase diagram has been constructed involving
spironolactone polymorphs I and II and its liquid phase.
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1.2. Available data from literature
Spironolactone (C⁠24H⁠32O⁠4S with M=416.57gmol⁠−1) is an aldos-
terone agonist used in human therapeutics as a diuretic. The suspi-
cion of spironolactone polymorphism arose about 50years ago due to
infrared spectroscopic measurements (Mesley and Johnson, 1965). In
1972, the crystal structure of a polymorph grown from an acetone
solution was solved and thus called form I (Dideberg and Dupont,
1972). With differential scanning calorimetry (DSC), it was observed
that spironolactone crystallized from ethanol or from water exhibited a
small exothermic peak at about 433K and an endothermic peak at about
483K, whereas spironolactone crystallized from methanol exhibited an
endothermic peak at about 393K followed by an exothermic peak at
about 413K (Sutter and Lau, 1975). These and other literature data have
been compiled in Table 2. Below follows a summary description of the
findings in the literature.
In 1976, Florence and Salole demonstrated that pre-melting behavior
observed by DSC was radically altered by grinding (Florence and Salole,
1976). They subjected a commercial specimen to differential thermal
analysis (DTA) at a 10Kmin⁠−1 heating rate and recorded an endother-
mic peak (onset at about 423K) followed by an exothermic peak (on-
set at about 433K) and a melting peak at about 483K (Florence and
Salole, 1976). Unfortunately, no X-ray data was reported, making it dif-
ficult to link the observed thermal behavior to a specific polymorph. In
the 1980s, further investigations into the solid state of spironolactone
were carried out confirming the existence of multiple polymorphs in ad-
dition to a number of solvates (Eldalsh et al., 1983; Salole and Alsarraj,
1985a,b). In the early 1990s, the polymorphism of spironolactone and
its solvation was revisited by Agafonov et al. (Agafonov et al., 1991a;
Agafonov et al., 1991b), who previously had solved the crystal struc-
ture of a second polymorph (thus named form II) using crystals grown
from an acetone solution (Agafonov et al., 1989). Berbenni et al. found
melting temperatures ranging from 480 to 486K and melting enthalpies
from 44 to 54Jg⁠−1 obtained from four solvent-free samples; however,
their different X-ray powder diffraction patterns were not indexed and
the samples were listed as polymorphs ‘M’, ‘EV’, ‘E’ and ‘A’, respec-
tively (Berbenni et al., 1999). Moreover, Berbenni et al. and Marini et
al. reported that spironolactone decomposes in the melt (Berbenni et al.,
1999; Marini et al., 2001), which obviously may affect the values of the
melting enthalpies and the melting point of form II.
In 2003, high resolution X-ray powder diffraction experiments as a
function of temperature demonstrated that form II exhibits no structural
change up to its fusion, whereas form I transforms into form II in the
373–398K temperature interval (Liebenberg et al., 2003). In 2007, a
I→ II transformation was observed with an onset in the 373–393 tem-
perature interval and with a liquid as an intermediate phase, which
was interpreted as a melting recrystallization (Espeau et al., 2007).
Summing over the complete endo-exothermic effect resulted in a value
of 0±2Jg⁠−1 for the enthalpy of the I→ II transition at the tempera-
ture of fusion of form I leaving the relative enthalpy ranking between
the two phases undetermined (Espeau et al., 2007). The melting en-
thalpy of form II, Δ⁠II→LH=55Jg⁠−1 at 480K (onset), was found to be
close to previous values. In addition, specific volumes of forms I, v⁠I,
and II, v⁠II, were determined as a function of temperature in the range
from room temperature up to their respective melting points (Espeau
et al., 2007). At 300K, those equations lead to the specific volumes
v⁠I (300K)=0.78942cm⁠3 g⁠−1 and v⁠II (300K)=0.80099cm⁠3 g⁠−1, which
1 With ordinary pressure is meant that the system is not subjected to a pressure, but
allowed to determine its own equilibrium pressure.
clearly demonstrates that form I is denser than form II. Fukuoka et al. in
1991 found a glass transition for spironolactone at T⁠g =331K (Fukuoka
et al., 1991), rather different from the value of 364K reported by Mahlin
and Bergström in 2013 (Mahlin and Bergstrom, 2013).
There is no doubt that the phase behavior of spironolactone is chal-
lenging to study and except for the melting of form II uncertainty ex-
ists about the rest of its phase behavior. Seventy degrees of difference
appears to exist between the melting temperatures of forms I and II
and still form I can be easily obtained experimentally. Moreover, as can
be judged from the specific volumes, form I is the densest polymorph
and clearly less stable than form II; this is in obvious contradiction
with the density rule proposed by Burger and Ramberger (Burger and
Ramberger, 1979a,b). In the present paper an attempt will be made to
shine some light on the phase behavior of spironolactone by construct-
ing a pressure-temperature phase diagram. Most likely, the last word is
not written about the exact calorimetric data of the phase behavior of
spironolactone, but using data from the literature and additional mea-
surements, it will be shown that despite the 70 degrees of difference in
melting points, form I does possess a stable domain in the pressure-tem-
perature phase diagram.
2. Material and methods
2.1. Sample of forms I and II
Samples of medicinal grade from Sanofi (France) and from Welding
GMBH (Germany), purity >99%, were respectively found to consist of
pure form II and pure form I by X-ray diffraction and used as such. In
addition, crystals of form I were grown by evaporating solutions of form
II in ethanol at room temperature, in accordance with the method de-
scribed previously (Nicolai et al., 2007). A thermogravimetric curve of
the latter form I has been provided in the supplementary materials, Fig.
S2.
2.2. High resolution X-ray powder diffraction
High-resolution X-ray diffraction patterns were recorded at room
temperature with cylindrical position-sensitive detectors (CPS120) from
INEL (France) using monochromatic Cu-Kα⁠1 (λ=1.54061Å) radiation.
Fig. 2 demonstrates that the experimental diffraction patterns exhibit no
differences with the respective calculated patterns based on the crystal
structures.
2.3. Differential scanning calorimetry
Temperatures and heats of fusion were determined at various heat-
ing rates with a TA-Instruments Q100 thermal analyzer. Indium
(T⁠fusion =429.75K, Δ⁠fusionH=28.45Jg⁠−1) was used as a standard for
temperature and enthalpy calibration.
Specific heat capacities as a function temperature were determined
with the TA-Instruments Q100 using a modulated signal by superimpos-
ing a sinusoidal temperature change on the linear temperature increase.
The linear heating rate was 2Kmin⁠−1 while the superimposed sinusoidal
had an amplitude of ±0.5K and a period of 60 s. Vitreous spironolac-
tone was obtained after heating specimens at 100Kmin⁠−1 up to 490K
and quenching them to room temperature within a few seconds to avoid
decomposition. The so-obtained colorless transparent glass was ground
into a powder and subjected to modulated DSC experiments from 220K
to 430K.
Samples were weighed using a microbalance sensitive to 0.01mg
and sealed in aluminum pans.
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Table 1
Melting point differences between polymorphs of the same compound since the publication of Burger and Ramberger (Burger and Ramberger, 1979b).
T⁠fus(i)/K T⁠fus(j)/K ΔT Ref.
1 Metacetamol 420.5 (I) 400 (II) 20.5 McGregor et al. (2015)
420.6 (I) 399.4 (II) 21.2 Barrio et al. (2017a)
2 Racemic m-nisoldipine 408.95 402.4 6.5 Yang et al. (2012)
410.94 403.31 7.63 Yang et al. (2013)
3 Apatinib mesylate 469.56 462.84 6.72 Zhu et al. (2016)
4 Olopatadine HCl 526.12 523.19 2.93 Laszcz et al. (2016)
5 Nimesulide 422.4 419.8 2.6 Barrio et al. (2017c)
6 Racemic Fluoxetine nitrate 385 383 2 Carvalho et al. (2016)
7 Acedapsone 565.95 (I)
565.95 (I)
556.65 (III)
561.85 (II)
9.3
4.1
Bolla et al. (2014)
8 Cimetidine 426 (B)
426 (B)
419.5 (D)
423.5 (A)
6.5
2.5
Shibata et al. (1983)
9 Ranitidine 350.84 (II) 346.65 (I) 4.19 De Armas et al. (2009)
10 Ranitidine HCl 410.95 (2) 408.75 (1) 2.2 Mirmehrabi et al. (2004)
11 Ticagrelor 422 (I)
422 (I)
402.5 (III)
410.5 (II)
19.5
11.5
Bohlin et al. (2007)
12 4′-Hydroxyacetophenone 381.9 (I) 377.2 (II) 4.7 Joseph et al. (2017)
13 3,3′-Diindolylmethane 440 (II) 436 (I) 4 Latosinska et al. (2016)
14 m-Aminobenzoic acid 451.13 (II) 445.19 (I) 5.94 Svard et al. (2010)
15 SSR180711C 448.0 (I) 446.7 (II) 1.3 Robert et al. (2016)
16 Piracetam 426 (I) 412 (III) 14 Céolin et al. (1996)
17 Rotigotine 370 (II) 350 (I) 20 Rietveld and Ceolin (2015)
18 FK664 413 (B) 388 (A) 25 Miyamae et al. (1991)
19 Ritonavir 398.15 (II) 395.15 (I) 3 Chemburkar et al. (2000)
20 Rimonabant 429.2 (II) 428.3 (I) 0.9 Perrin et al. (2013)
21 Bicalutamide 465.6 (I) 462.9 (55) 2.7 Gana et al. (2013)
22 Benfluorex HCl 433.64 (I) 427.48 (II) 6.16 Maccaroni et al. (2010)
23 Biclotymol 400.5 (I) 373.8 (II) 26.7 Ceolin et al. (2008)
24 Fananserine 375.1 (II)
375.1 (II)
375.1 (II)
366.3(I)
374.8 (III)
372.8 (IV)
8.8
0.3
2.3
Giovannini et al. (2001)
25 Aprepitant 526.75 (I) 526.15 (II) 0.6 Braun et al. (2008b)
26 N-Picryl-p-toluidine 439.25 (Ig) 436.65 (IIo) 2.65 Braun et al. (2008a)
27 Aripiprazole 421.65 (I)
421.65 (I)
421.65 (I)
408.15 (IV)
416.15 (II)
412.35 (III)
13.55
5.5
9.3
Braun et al. (2009)
28 Nembutal 402.65 (I)
402.65 (I)
402.65 (I)
382.15 (IV)
399.15 (II)
387.15 (III)
20.5
3.5
15.55
Rossi et al. (2012)
29 Methylparaben 399.15 (1-I)
399.15 (1-I)
399.15 (1-I)
380.15 (1–107)
385.15 (1–112)
382.15 (1-III)
19
14
17
Gelbrich et al. (2013)
30 7-Hydroxyisoflavone 488.15(II) 482.75 (I) 5.4 Gong et al. (2016)
31 Irganox 1076® 324.15 (I)
324.15 (I)
324.15 (I)
278.45 (IV)
324.05 (II)
320.35 (III)
45.7
0.1
3.8
Saunier et al. (2010)
32 Lifibrol 415 (I) 408 (II) 7 Burger and Lettenbichler (2000)
33 Praziquantel 415.71 (A) 385.25 (B) 30.46 Zanolla et al. (2018)
34 Albendazole 493 (I) 433 (II) 60 Pranzo et al. (2010)36
35 Theophylline 546.55 (I) 542.25 (II) 4.3 Suzuki et al. (1989)
36 Atomoxetine HCl 441.05 (I) 437.45 (II) 3.6 Stephenson and Liang (2006)
37 Bentazon 413 (II)
413 (II)
400 (III)
405 (I)
13
8
Braga et al. (2014)
38 Felodipine 418.05 (III)
418.05 (III)
407.05 (I)
414.70 (II)
11
3.35
Srcic et al. (1992)
39 Auranofin 389 (B) 385 (A) 4 Lindenbaum et al. (1985)
40 MK571 437 (I) 425 (II) 12 Ghodbane and Mccauley (1990)
41 WIN 63843 (pleconaril) 337.65 (I) 334.35 (III) 3.3 Rocco and Swanson (1995)
42 Sulfapyridine 459.45 (I) 450.45 (II) 9 Bottom (1999)
43 Benzidine 401 (II) 397 (I) 4 Rafilovich and Bernstein (2006)
44 Buspirone HCl 476.75 (2) 462.95 (1) 13.8 Sheikhzadeh et al. (2006)
45 Cilostazol 432.0 (A)
432.0 (A)
408.8 (B)
419.0 (C)
23.2
13
Stowell et al. (2002)
46 Curcumin 450.72 (1)
450.72 (1)
441.44 (3)
445.10 (2)
9.28
5.62
Sanphui et al. (2011)
47 Diniflusal 486.30 (D)
486.30 (D)
485.45 (B)
485.95 (A)
0.85
0.35
Perlovich et al. (2002)
48 Donepezil 367.39 (F)
367.39 (F)
367.39 (F)
362.42 (C) 363.82 (I)
367.09 (II)
4.97
3.57
0.30
Park et al. (2013)
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Table 1 (Continued)
T⁠fus(i)/K T⁠fus(j)/K ΔT Ref.
49 Doxazosin mesylate 551.05 (A)
551.05 (A)
551.05 (A)
551.05 (A)
551.05 (A)
501.1 (D)
549.65 (F)
543.95 (G)
531.15 (H)
548.05 (I)
49.95
1.40
7.1
19.9
3
Grcman et al. (2002)
50 Famotidine 440.05 (A) 432.05 (B) 8 Lu et al. (2007)
51 Florfenicol 427.5 (B) 425.45 (A) 2.05 Sun et al. (2014)
52 Fluconazole 412.85 (A) 412.05 (B) 0.8 Gu and Jiang (1995)
53 Racemic flurbiprofen 386.65 (I)
386.65 (I)
360.10 (III)
365.15 (II)
26.55
21.5
Henck and Kuhnert-Brandstatter (1999)
54 Formoterol fumarate 423 (B)
423 (B)
396 (C)
400 (A)
27
20
Jarring et al. (2006)
55 Ibopamin 408.39 (I) 403.85 (II) 4.54 Laine et al. (1995)
56 Lamivudine 451 (II) 408 (I) 43 Jozwiakowski et al. (1996)
57 Linezolid 453 (IV) 428 (II) 25 Maccaroni et al. (2008)
58 Malotilate 335 (B) 325 (A) 10 Vega and Baggio (1989)
59 Metazachlor 356 (I)
356 (I)
356 (I)
356 (I)
338 (V)
353 (II)
349 (III)
346 (IV)
18
3
7
10
Griesser et al. (2004)
60 Metoclopramide HCl 460 (I) 428 (II) 32 Mitchell (1985)
61 Nateglinide 447.25 (S)
447.25 (S)
402.35 (B)
411.05 (H)
44.9
36.2
Bruni et al. (2009)
62 Nicardipine Hydrochloride 457 (α) 438 (β) 19 Moreno-Calvo et al. (2011)
63 RS-Nitrendipine 430 (I)
430 (I)
398 (III)
405 (II)
32
25
Burger et al. (1997)
64 Pemetrexed Diacid 408.43 (1) 397.32 (2) 11.11 Michalak et al. (2015)
65 Piperine 405.64 (I)
405.64 (I)
389.63 (III)
401.12 (II)
16.01
4.52
Pfund et al. (2015)
66 Piretanide 500 (A) 486 (B) 14 Chikaraishi et al. (1994)
67 Piroxicam 475.75 (I) 472.85 (II) 2.9 Vrecer et al. (2003)
68 Premafloxacin 471 (III)
471 (III)
416 (I)
439 (II)
55
32
Schinzer et al. (1997)
69 Salicaine hydrochloride 429.15 (I) 425.35 (II) 3.65 Schmidt et al. (2006)
70 Salmeterol Xinafoate 410.75 (II) 395.85 (I) 14.9 Tong et al. (2001)
71 Sofosbuvir 395.37 (B) 393.89 (A) 1.48 Qi et al. (2015)
72 Sulindac 460 (I) 456(II) 4 Tros de Ilarduya et al. (1997)
73 Tegafur 448 (γ) 438 (δ) 10 Uchida et al. (1993)
74 Telmisartan 542 (A) 456 (B) 86 Dinnebier et al. (2000)
75 Temazepam 433.85 (O)
433.85 (O)
411.65 (VI)
432.45 (X)
22.2
1.4
Jetti et al. (2011)
76 Terazosin hydrochloride 544.15 (II)
544.15 (II)
544.15 (II)
540.45 (I)
543.55 (IV)
541.65 (III)
3.7
0.6
2.5
Bauer et al. (2006)
77 Terfenadine 422 (I)
422 (I)
422 (I)
416.5 (IV)
421 (II)
418 (III)
5.5
1
4
Leitao et al. (2002)
78 Racemic thalidomide 548.35(β) 545.45 (α) 2.9 Reepmeyer et al. (1994)
549.75 (β) 548.65 (α) 1.1 Lara-Ochoa et al. (2007)
79 Tolbutamide 401 (I⁠H) 390 (II) 11 Thirunahari et al. (2010)
400.3 (I ⁠H) 375.73 (V) 24.57 Svard et al. (2016)
80 Tulobuterol 364 (1) 354 (2) 10 Caira et al. (2004a)
81 Varenicline L-tartrate 497.15 (A) 489.05 (B) 8.1 Murphy et al. (2010)
82 Stavudine 441.25 (I) 438.65 (II) 2.6 Lu and Rohani (2009)
83 Chenodeoxycholic acid 439 (I) 392 (III) 47 Oguchi et al. (2003)
84 ASP3026 453 (A04)
453 (A04)
433 (A01)
443 (A03)
20
10
Takeguchi et al. (2015)
85 Benoxaprofen 466 (II) 460 (I) 6 Umeda et al. (1984)
86 HOKU-81 454 (II) 452 (I) 2 Saito et al. (1983)
87 Tulobuterol HCl 443 (II)
443 (II)
422 (III)
436 (I)
21
7
Saito et al. (1982)
88 (R,S)-Propranolol HCl 439 (I) 436(II) 3 Bartolomei et al. (1998)
89 m-Anisic acid 378.55 (I) 367.15 (II) 11.4 Pereira-Silva et al. (2015)
90 Ambroxol 372.65 (I) 365.55 (II) 7.1 Caira et al. (2004b)
91 Racemic betaxolol 342.15 (I) 306.55(II) 35.6 Maria et al. (2013)
92 Bromopride 428 (I) 376 (II) 52 Carrer et al. (2016)
93 Bisoprolol fumarate 378.65 (I) 369.75 (II) 8.9 Detrich et al. (2018)
94 Delapril HCl 452.75 (D1) 438.15 (D2) 14.6 Todeschini et al. (2014)
95 Manidipine HCl 494.05 (M1) 492.05 (M2) 2 Todeschini et al. (2014)
96 Febantel 397.05 (I) 387.55 (II) 9.5 Bruni et al. (2017)
97 Prilocaine HCl 442 (I) 438.5 (II) 3.5 Schmidt et al. (2004)
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Table 1 (Continued)
T⁠fus(i)/K T⁠fus(j)/K ΔT Ref.
98 p-Methylchalcone 369.45 (I) 362.55 (II) 6.9 Barsky et al. (2008)
99 Nabumetone 353 (I) 338(II) 15 Price et al. (2002)
100 Metaxalone 395.35 (B) 395.05 (A) 0.3 Aitipamula et al. (2011)
101 Etiracetam 392.39 (II) 385.44 (I) 6.95 Herman et al. (2011)
102 Cefamandole nafate 442.5 (IV) 437.0 (V) 5.5 He et al. (2016)
103 Risperidone 443.26 435.25 8.01 Pfeiffer et al. (2003)
104 3,3′-Dihydroxy-β,β-carotene-4,4′-dione 503 (I) 489 (II) 14 Guo and Ulrich (2010)
105 Neotame 385 (G)
385 (G)
365 (A and F) 367 (D) 20
18
Dong et al. (2002)
106 Imatinib mesylate 499 (α) 490 (β) 9 Grillo et al. (2012)
107 NCX4016 335 (I) 328.3 (II) 6.7 Foppoli et al. (2004)
108 Succinobucol 430 (A)
430 (A)
430 (A)
408.6 (E)
420.7 (C)
413.2 (D)
21.4
9.3
16.8
Jurcek et al. (2012)
109 Alprazolam 500.17 (III) 495.15 (I) 5.02 De Armas et al. (2007)
110 Nortryptiline HCl 490.1 (α) 490.0 (β) 0.1 Vladiskovic et al. (2012)
111 Febuxostat 482.89 (I)
482.89 (I)
474.19 (III)
476.30 (II)
8.70
6.50
Patel et al. (2015)
112 Carnidazole 418.25 (I) 411.05 (II) 7.2 de Armas et al. (2006)
113 Nicergoline 407 (I) 394 (II) 13 Malaj et al. (2011)
114 E2101 421.25 (I) 412.95 (II) 8.3 Kushida and Ashizawa (2002)
115 Celecoxib 434 421 13 Lu et al. (2006)
116 Piroxicam pivalate 426.95 (1) 409.65 (2) 17.3 Giordano et al. (1998)
117 LY334370 HCl 547 (I)
547 (I)
463 (II)
538 (III)
84
9
Reutzel-Edens et al. (2003)
118 Clopidogrel Bisulfate 454.35 (I) 449.25 (II) 5.1 Khomane et al. (2012)
119 Irganox 3114® 492 (I) 478 (II) 14 Saunier et al. (2012)
120 Probucol 399 (I)
399 (I)
381 (III)
389 (II)
18
10
Kawakami and Ohba (2017)
121 Suplatast tosilate 359.85 (α)
359.85 (α)
359.85 (α)
359.85 (α)
359.85 (α)
347.95 (δ)
359.65 (γ)
356.15 (η)
351.25 (ζ)
348.35 (ε)
11.9
0.2
3.7
7.9
11.5
Nagai et al. (2014)
122 Sitafloxacin 513 (α) 493K (β) 20 Suzuki et al. (2010)
123 l-arabitol 374 (I) 353 (II) 21 Carpentier et al. (2013)
124 Amisulpride 398.45 (I) 395.85 (II) 2.6 Zhang and Chen (2017)
125 Ciprofloxacine Saccharinate 573.95 (I) 567.45 (II) 6.5 Singh and Chadha (2017)
126 DuP 747 491.3 (II) 483.6 (I) 7.7 Raghavan et al. (1994)
127 (-)-N-Methylephedrine 360.8 (I) 359.6 (II) 1.2 Tulashie et al. (2016)
128 Venlafaxine HCl 483.99 (1) 481.21 (2) 2.78 Roy et al. (2005)
491.97 (6) 481.55 (1) 10.42 Roy et al. (2007)
129 Venlafaxine 351.25 (III)
351.25 (III)
348.05 (I)
349.65 (II)
3.2
1.6
van Eupen et al. (2009)
Fig. 1. Number of polymorph pairs as a function of the temperature difference (ΔT) be-
tween the melting temperature of the most stable polymorph and a metastable one com-
piled by Burger and Ramberger in yellow (Burger and Ramberger, 1979b) and more recent
data in blue (see also Table 1). ΔT is smaller than 15K for 75% of the pairs and only 2
pairs (less than 1%) exhibit a difference of more than 80 °C in melting points. The melting
difference of spironolactone is marked in red.
3. Results
3.1. Calorimetric data
For comparison with the melting data from the literature (Table 2),
DSC measurements with 15 separate samples of form II were carried
out (Table 3) demonstrating that the present sample of form II melts
at 479.6±0.6K with a melting enthalpy of Δ⁠II→LH=54.0±1.5Jg⁠−1
(22.49±0.62kJmol⁠−1) i.e. close to the previously reported values of
480K and 55Jg⁠−1, respectively, in reference (Espeau et al., 2007).
Form I was obtained from the Sanofi batch by evaporating an
ethanol solution and its transformation behavior is represented by curve
3 in Fig. 3. Part ‘a’ of the convoluted phenomenon ‘ab’ is the onset of
the melting of form I, however, it is taken over half way by the recrys-
tallization of form II (part ‘b’). This behavior has been reported pre-
viously in the literature, however at that time it could not be deter-
mined whether the I→ II transformation had a positive or a negative en-
thalpy (Espeau et al., 2007). In the present case, summation over the
endo-exothermic effect (peaks ‘a’ and ‘b’ in Fig. 3) results in Δ⁠I→IIH
values ranging from +2.1 to −11.7Jg⁠−1 depending on the run and the
mean over 7 values is −4.3±4.0Jg⁠−1 with all enthalpy values except
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Table 2
Calorimetric data on spironolactone in the literature.⁠a
T⁠g/K T⁠I→II/K T⁠I→L/K T⁠cryst/K T⁠II→L/K Δ⁠I→II H/Jg⁠−1 Δ⁠I→L H/Jg⁠−1 Δ⁠II→L H/Jg⁠−1 reference
433 (exo) 483 Sutter and Lau (1975)
393? 393? 413 (exo) Sutter and Lau (1975)
423?⁠b 433 (exo) ⁠b 483⁠b Florence and Salole (1976)
478? 483 48? 53 Agafonov et al. (1991a), Agafonov et al. (1991b)
480–486 44–54 Berbenni et al. (1999)
50.8±1.5 Marini et al. (2001)
480 51.93 Pisegna (1999)
373–398 (Xr) Liebenberg et al. (2003)
481.15 51.3±1.3 Snider et al. (2004)
373–393? 373–393? 480 0±2 55
475–476⁠c 35.79–51.86⁠c Brandão et al. (2008)
481 54.1 Dong et al. (2009)
453–473⁠d 476.5⁠d 44.5⁠d Dong et al. (2009)
331 Fukuoka et al. (1991)
364 486 60 Mahlin and Bergstrom (2013)
481.57 49.58 Zhang et al. (2014)
481.9–483.1 49.58–50.82 Jiang et al. (2015)
475.9 45.2 de Resende et al. (2016)
a Transitions are endothermic unless otherwise specified, transition temperatures are obtained by DSC unless otherwise specified (Xr: X-ray diffraction), values of which the
interpretation is not clear or in doubt are marked with a question mark.
b Ground sample.
c Microparticles.
d “micrometer sized nanoparticles” [sic] (Dong et al., 2009).
Fig. 2. High-resolution X-ray powder diffraction patterns of spironolactone forms I and
II: exp: experimental pattern at 300K with form I from Welding and form II from Sanofi,
ethanol: sample from Sanofi recrystallized into form I, cal=calculated pattern based on
the crystallographic information files (CIF) from the Cambridge Structural Database (CSD)
with registry codes: form I=ATPRCL10, form II=ATPRCL01.
for one being negative (Table 3). The mean onset temperature of fusion
of form I, peak ‘a’, is T⁠I→L =408±3K (see Table 3).
Whereas form I of the spironolactone batch from Sanofi consis-
tently melted before recrystallization into form II, form I from Weld-
ing exhibited a single exothermic peak with a mean enthalpy change
of −6.9±0.3Jg⁠−1 and at a mean temperature of 375±3K (see curve
2 in Fig. 3 and Table 4). The single exothermic peak represents a di-
rect transformation of form I into form II and confirms beyond doubt
(Δ⁠I→IIH=−6.9±0.3Jg⁠−1) that the transition of form I into form II has
a negative enthalpy change.
The glass transition temperature T⁠g was found to be at 306K in the
present series of experiments, as can be seen in the inset of Fig. 3. This
temperature is near the value of 320K found with the empirical formula
by Tammann: T⁠g =2/3 T⁠fus.
3.2. Specific heats
The specific heats of form II and of the melt have been fitted in the
temperature range of 250K–450K and 325K–450K respectively (See
Supplementary Information), leading to:
(1)
(2)
Using these equations and extrapolating to the melting point of form
II at 479.6K, the relative enthalpies of the liquid and of form II have
been calculated as a function of the temperature (Fig. 4).
4. Discussion – interpretation of the results through a pressure-
temperature phase diagram
4.1. Global evaluation of the data and the phase behavior of spironolactone
It is clear from the introduction and the results that the phase be-
havior of spironolactone is not easy to understand. Based on the pre-
sent batches from Sanofi and Welding, one can consider that the melt-
ing point and melting enthalpy of form II are reasonably correctly de-
fined by the mean values in Table 3. The temperature of fusion for
form I possesses a larger uncertainty, but it can be considered to be in
the order of 408±3K. Obviously, the enthalpy of fusion for form I is
experimentally inaccessible as the melting peak and the recrystalliza-
tion peak are convoluted (Fig. 3); however, an estimate of this value
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Table 3
Onset temperatures and enthalpies of phase transitions obtained with the spironolactone sample from Sanofi.⁠a
Initial form Heating rate/Kmin⁠−1 T⁠I→L/K⁠b Δ⁠I→IIH⁠c/Jg⁠−1 T⁠II→L/K Δ⁠II→LH/Jg⁠−1
I 15 406.7 −11.7 479.8 54.3
I 20 408.2 −4.7 480.6 52.7
I 25 407.7 −3.8 479.7 53.9
I 30 408.1 −3.9 480.0 54.2
I 35 410.2 −4.1 479.9 54.7
I 40 403.4 −3.7 478.4 53.6
I 45 412.1 +2.1 480.3 53.3
I 15 405.6 – 479.8 58.3
II 15 479.2 53.2
II 20 478.5 53.2
II 25 478.8 56.1
II 30 479.6 52.5
II 35 479.3 54.6
II 40 479.7 52.9
II 45 479.8 53.1
Mean values (standard deviation) 408±3 −4.3±4.0 479.6±0.6 54.0±1.5
a The commercial form is form II, form I was prepared by evaporating an ethanol solution at room temperature.
b The onset of the first transition peak in the Sanofi sample is related to the melting of form I, see Fig. 3 for clarification.
c The overall enthalpy of the first transformation in the Sanofi sample is related to the combined conversion of form I into liquid and its recrystallization into form II, see Fig. 3 for
clarification.
Fig. 3. DSC curves with (1) the melting curve of commercial spironolactone form II, (2)
the irreversible (exothermic) transition of spironolactone form I to form II (sample from
Welding), and (3) the same transition through a melting (a)-recrystallization (b) process
(sample from Sanofi). Area ‘b’ is found to be greater than area ‘a’, leading to a negative
value for the transition enthalpy of form I to form II, as confirmed by negative area ‘c’.
Inset: glass transition observed at 306K by reheating the glass obtained from the melt.
will be calculated below in the discussion. Finally, the enthalpy differ-
ence between forms I and II is found equal to −6.9±0.3Jg⁠−1, although
in terms of accuracy, it is probably in the order of −6.9±1Jg⁠−1.
Before constructing the topological phase diagram, the phase be-
havior will be evaluated using the Le Chatelier principle. The behavior
Table 4
Calorimetric data (onset temperatures and enthalpies of phase changes) obtained with
spironolactone form I from Welding.
Sample T⁠I→II/K Δ⁠I→IIH/Jg⁠−1 T⁠II→L/K Δ⁠II→LH/Jg⁠−1
1 371.9 −6.2 – –
2 370.5 −6.4 477.2 53.6
3 375.8 −7.3 479.5 55.0
4 375.9 −7.3 479.2 55.8
5 376.0 −7.2 479.4 53.5
6 379.2 −6.2 479.3 54.9
7 377.7 −7.3 479.5 54.8
Mean 375±3 −6.9±0.3 479.0±1.0 54.6±0.9
Fig. 4. The relative enthalpy of form II and of the liquid obtained by numerical integra-
tion of the heat capacity data.
of spironolactone in relation to the pressure can be deduced from the
specific volumes of the two polymorphs (see introduction and (Espeau
et al., 2007)). Form I is the denser polymorph and therefore its relative
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stability will increase with pressure, whereas the relative stability of
form II will decrease. It implies that if a phase equilibrium exists, form
I will be stable at the high-pressure side and form II at the low-pres-
sure side. A similar analysis can be carried out in terms of the enthalpy
of form I and form II. The data from Tables 3 and 4 indicate beyond
reasonable doubt that form I possesses a higher absolute enthalpy than
form II, which implies that form I is the high temperature form. Inter-
estingly, it is form II that has the highest melting point and this leads to
the immediate conclusion that any equilibrium between forms I and II
will be located at a higher temperature than the melting point of form
II and thus this equilibrium will be metastable under normal pressure.
Hence, without any mathematical calculation, it can be concluded that
to accommodate the density and enthalpy requirements of the system,
the I-II phase equilibrium line necessarily possesses a negative slope (see
Fig. 5) with form I stable above the equilibrium and form II below. Fur-
thermore, it can be stated that this I-II phase equilibrium is located at
positive pressures (P≫0MPa) to accommodate for the fact that form II
exhibits the stable melting temperature. Finally, this leads to the con-
clusion that form II is the only stable form under ordinary conditions,
i.e. the equilibrium between form II and the vapor phase is stable from
0K up to its melting point (see Fig. 5). This result implies that unless
the data in the Tables 3 and 4 are substantially wrong, any calculated
phase diagram must obey the overall layout dictated by the Le Chatelier
principle as depicted in Fig. 5.
4.2. An equation describing the II-L equilibrium
A mathematical expression for a two-phase equilibrium line can be
obtained by using the Clapeyron equation and as the simplest expres-
sion for a monotonic function (Ceolin and Rietveld, 2017), a straight
line can be used. The melting point of form II is the best-documented
phase transition in the spironolactone system and the one that most
of the literature data seem to agree upon. The data in Table 3 will
be used, which is similar to the data in the literature discussed in the
introduction. To calculate the slope of the II-L equilibrium with the
Clapeyron equation, the volume change on melting is needed too, how-
ever, slow decomposition of spironolactone in the molten state pre-
vented the direct measurement of the specific volume of the liquid,
which necessitates high temperatures for considerable amounts of time.
Fig. 5. Schematic pressure-temperature phase diagram (not to scale) following the Le
Chatelier principle applied to the data in Tables 1 and 2. Arrow “a” represents the trans-
formation of form II into the denser form I on increasing pressure and arrow “b” represents
the endothermic transformation of form II into form I, which possesses the higher absolute
enthalpy. The phase equilibrium between forms I and II must have a negative slope to
accommodate a high-pressure, high-temperature phase I and a low-temperature, low-pres-
sure phase II. As a result, form II is the only stable phase under ordinary conditions, i.e.
the solid II – vapor equilibrium, up to its melting point (solid black circle). Solid lines: sta-
ble phase equilibria, dashed lines: metastable phase equilibria.
Nevertheless, several authors have reported mean values for the volume
change on melting for organic molecular compounds. Ubbelohde found
that the volume increase on melting ranges from 7 to 16% with a mean
value of 11.5%, a volume increase that has been confirmed by Gavez-
zotti (Gavezzotti, 2013; Ubbelohde, 1965). This value is very close to
the value of 12% proposed by Goodman et al. and to the mean value
of 10% found within 6 and 17% for several molecular solids of phar-
maceutical interest (Céolin and Rietveld, 2015; Goodman et al., 2004;
Rietveld and Céolin, 2015). It can be concluded that as an approxima-
tion, the volume change on melting of the highest melting polymorph
can be taken as 11% of its specific volume.
The specific volume of polymorph II at its melting point of 479.6K
can be calculated using data from Espeau et al. (Espeau et al., 2007)
and leads to a value of 0.8291cm⁠3 g⁠−1. The volume change on melting is
taken as 11% of this value, which equals Δ⁠II→Lv=0.0912 cm⁠3g⁠−1, which
leads to 0.9203cm⁠3 g⁠−1 for the value of the specific volume of the melt.
With the volume change, the enthalpy change, Δ⁠II→LH=54.0Jg⁠−1, and
the melting temperature, the slope in the pressure-temperature plane,
dP/dT, for the two-phase equilibrium II-L can be calculated resulting
in 1.23MPaK⁠−1. Using P=0MPa at T⁠II→L =479.6K, because the va-
por pressure at the melting point is necessarily smaller than 1atm (=
0.1MPa), one can obtain a linear expression for the equilibrium be-
tween form II and the liquid as a function of pressure and temperature:
(3)
4.3. An equation describing the I-L equilibrium
To formulate a mathematical description for the I-L equilibrium line,
its equilibrium temperature, the enthalpy change on melting and the
volume change on melting are needed for the Clapeyron equation. The
equilibrium temperature is the melting point reported in Table 3. The
enthalpy change on melting or the heat of fusion will have to be calcu-
lated, making use of the heat capacity Eqs. (1) and (2). In addition, for
the volume change on melting, the specific volume of the melt needs
to be determined. These two inequalities between form I and the liq-
uid, Δ⁠I→LH and Δ⁠I→Lv, will be calculated below using a few approxima-
tions. Obviously, approximations will increase the incertitude over the
accuracy of the final expression. Nonetheless, considering Fig. 5, it is
clear that the resulting expression for the I-L equilibrium should meet
the II-L equilibrium at high pressure, because that is where the I-II and
II-L equilibria meet (Fig. 5). The intersection of I-II and II-L will result
in the triple point I-II-L and this triple point is part of the I-L equilib-
rium too. It implies that the Clapeyron equation must result in a slope
dP/dT<1.23MPaK⁠−1, the slope of the II-L equilibrium.
4.3.1. Heat of fusion of form I
The heat of fusion of form I can only be determined indirectly, be-
cause of the immediate recrystallization of its melt into form II (Sanofi
sample) or its direct transformation into form II (Welding sample). It ne-
cessitates the use of the specific heats as provided by Eqs. (1) and (2).
First, the heat of fusion of form II is obtained at the melting point of
form I, using the Kirchhoff equation:
(4)
in which is the change in
the difference in enthalpy between form II and the liquid when going
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from the melting point of form II (T⁠II→L) to the melting point of form I
(T⁠I→L). Using the data from Table 3, the respective melting points are
T⁠II→L =479.6K and T⁠I→L =408K. The change in the enthalpy using Eqs.
(1) and (2) leads to (See Eqs. (S.3)–(S.7)
in the supplementary information). Taking into account the melting en-
thalpy of form II at its melting point, ΔH⁠II→L (T⁠II→L)=54.0Jg⁠−1, the
melting enthalpy of form II at the melting temperature of form I be-
comes ΔH⁠II→L (T⁠I→L) = 46.5Jg⁠−1.
The enthalpy of fusion of form I, ΔH⁠I→L, can be found using the
property of a function of state that its value is only determined by
the initial and final conditions and the path does not affect its value:
ΔH⁠I→L =ΔH⁠I→II +ΔH⁠II→L and thus ΔH⁠I→L =(−6.9)+46.5=39.6Jg⁠−1.
The enthalpy change between form I and form II, ΔH⁠I→II, is here taken
as −6.9Jg⁠−1 (Table 4), as the change in the difference in the specific
heat capacity between the two solids is expected to be small and T⁠I→II
and T⁠I→L are relatively close.
4.3.2. Specific volume of the liquid as a function of the temperature
The specific volume of the melt at the melting point of form I is nec-
essary to calculate the change in the specific volume on the melting of
form I. Sufficiently far from the critical point, the temperature depen-
dence of v⁠L is usually described by a straight line: v⁠L =v⁠0 +(a⁠v,L·v⁠0)·T
with v⁠0 the specific volume at T=0K and a⁠v,L a measure for the slope
relative to v⁠0. In the case of spironolactone, an approximation for this
expression can be obtained by using the volume of the liquid at the melt-
ing point of form II (see the discussion above on the slope of the II-L
equilibrium line) and statistical information on the difference in the spe-
cific volume between its glass and its crystalline solid at the glass tran-
sition temperature (T⁠g), the former being 6% larger. Very few data are
available in the literature, however, a few glass – crystal volume differ-
ences obtained from experiment have been recently reported for a num-
ber of pharmaceuticals (see Table 5).
There is a large spread in the glass transition temperatures ob-
tained for spironolactone. In the literature, values of 331K (Fukuoka et
al., 1991) and 364K (Mahlin and Bergstrom, 2013) have been found,
whereas in the present experiments T⁠g was found to be 306K. Because
the latter value was obtained together with the other data in Table 1
that have been used for the calculations, 306K, will be used. For a
higher T⁠g, the slope of the specific volume of the liquid, dv⁠L/dT, will be
steeper and the specific volume of liquid spironolactone will be some-
what smaller at the melting point of form I, thus decreasing the volume
difference between the solid and the liquid. Because the volume differ-
ence is found in the denominator of the Clapeyron equation, a smaller
difference will make the slope of the I-L phase equilibrium steeper. Fol-
lowing the arguments in the first section of the discussion, the slope
can never be larger than 1.23MPaK⁠−1, as in that case the two phase
equilibria I-L and II-L will intersect at negative pressure and that would
Table 5
Volume changes of pharmaceuticals at melting points and glass transition temperatures
obtained from experiment.
v⁠L/v⁠I at
T⁠I→L T⁠I→L/K
v⁠L/v⁠I at
T⁠g T⁠g/K Ref.
Biclotymol 1.13 400.5 1.05 294 Ceolin et al.
(2008)
Ternidazole 1.11 333.0 1.07 235 Mahé et al.
(2011)
Morniflumate 1.12 348.1 1.06 249 Barrio et al.
(2017d)
Rimonabant 1.11 429.2 1.04 350 Perrin et al.
(2013)
Prilocaine 1.13 311.5 1.07 218 Rietveld et al.
(2013)
Paracetamol 1.15 442.3 1.07 298 Espeau et al.
(2005)
invalidate the rather basic observations on which the phase diagram in
Fig. 5 is based.
The specific volume of the melt at T⁠II→L is 0.9203cm⁠3 g⁠−1 as de-
termined above. If the specific volume of the glass at T⁠g is 6% larger
than the stable crystalline form, it can be calculated evaluating the
specific volume of form II (Espeau et al., 2007) at T⁠g =306K lead-
ing to v⁠II(T⁠g)=0.8019cm⁠3 g⁠−1 and for the liquid at the glass transition
v⁠L =0.8500cm⁠3 g⁠−1. This data can be used to obtain a linear expression
for the specific volume of the liquid as a function of the temperature:
(5)
4.3.3. An equation for the I-L equilibrium and triple point I-II-L
With Eq. (5), v⁠L at T⁠I→L =408K is found to be 0.8913cm⁠3 g⁠−1. At
this temperature, v⁠I equals 0.8034cm⁠3 g⁠−1 (Espeau et al., 2007), which
leads to a volume change, Δ⁠I→Lv of 0.0879 cm⁠3g⁠−1 on melting of form
I. Using this volume difference together with Δ⁠I→LH=39.6Jg⁠−1 at the
I-L equilibrium temperature T⁠I→L =408K in the Clapeyron equation, the
slope of the I-L equilibrium is found to be 1.11MPaK⁠−1, which is in-
deed smaller than the slope of equilibrium II-L confirming that the two
equilibria converge on increasing pressure and temperature. Setting the
pressure P equal to 0MPa at T⁠I→L, a linear expression of the I-L equilib-
rium can be obtained:
(6)
Using Eqs. (3) and (6), the triple point coordinates of I-II-L are found
to be T⁠I-II-L =1094K and P⁠I-II-L =758MPa.
In the case that 364K is used as the glass transition temperature,
which is the highest value found in the literature (Mahlin and
Bergstrom, 2013), it would result in an expression for the I-L equi-
librium of P=1.23T−500 and the triple point would be found at
T=9875K and P=11600MPa. This is obviously much larger than the
triple point coordinates calculated with Eq. (6), because for T⁠g =364K,
the slope of the I-L equation becomes only a fraction smaller than the
slope of II-L; nonetheless, it does not invalidate the schematic phase di-
agram based on the principle of Le Chatelier in Fig. 5.
4.4. An equation for the I-II equilibrium line
As concluded in Section 4.1, the slope dP/dT of the I-II equilibrium
line is negative with form I stable above and on the right-hand side
of the equilibrium line and form II stable below the equilibrium line
and on its left-hand side. Because the triple point I-II-L obtained with
Eqs. (3) and (6) is rather high in pressure and temperature, it is not
possible to obtain reliable calorimetric data on the I-II slope. A sim-
ple estimate can be obtained by considering that the enthalpy of transi-
tion Δ⁠I→IIH=−6.9Jg⁠−1. This enthalpy has been obtained at a tempera-
ture of 375K, hence an estimate of the entropy involved is −0.018Jg⁠−1
K⁠−1. Taking the volume difference between the two solid phases at
this temperature leads to 0.0136cm⁠3 g⁠−1. With the Clapeyron equation,
these data result in a rough estimate of the slope of the I-II equilib-
rium of −1.4MPaK⁠−1. This slope can be tentatively used to obtain an
expression for the I-II phase equilibrium located at the I-II-L triple point
(T=1094K and P=758MPa). It results in the following estimate for
the I-II phase equilibrium:
(7)
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With this last equation, the complete topological phase diagram of
the two solid phases of spironolactone can be described (Fig. 6).
5. Concluding remarks
The topological pressure-temperature phase diagram of spironolac-
tone describing the phase relationships between forms I and II of
spironolactone is presented in Fig. 6. As stated in the beginning of the
discussion, the I-II equilibrium line is located at high pressure. The only
stable phase of importance for drug formulations is form II, which is
stable over the entire temperature range under ordinary pressure (solid
line c – 1 in Fig. 6).
The phase diagram in Fig. 6 has not been easily obtained, because
the transformation of form I into form II through the liquid phase was
difficult to interpret with a previous publication reporting a difference
in enthalpy between the two polymorphs in the order of 0Jg⁠−1. In the
present paper, the observation of a direct transformation of form I into
form II without an intermediate liquid phase made it possible to con-
clude that the enthalpy change is negative for the I→ II transformation.
Another difficulty is the wide range of observed glass transition temper-
atures, which still lacks a clear explanation.
Despite of the difficulties in obtaining reliable data, the topological
phase diagram as represented in Fig. 6 has been confirmed in two ways.
Firstly, the obtention of the negative enthalpy difference for the trans-
formation of form I into form II and the specific volume data of the two
solid forms have led unequivocally to the schematic phase diagram in
Fig. 5. Secondly, the calculations using the Clapeyron equation demon-
strating the intersection of the two solid – liquid equilibria at high pres-
sure and temperature confirm the topological result obtained through
the Le Chatelier principle. Unfortunately, the experimental data on the
melting equilibrium of form I and the metastable I-II transition is not
precise enough to accurately define the I-II-L triple point, which remains
an estimate. Subsequently, the I-II equation, which depends on the loca-
tion of the I-II-L triple point, can only be tentatively described, even if it
is clear that its slope is negative.
An exothermic transformation of one solid form into another has
previously been observed for biclotymol, however in that case the two
melting equilibria diverge and only a single stable polymorph exists:
overall monotropy (Ceolin et al., 2008). The phase diagram of spirono-
lactone is surprisingly similar to that of paracetamol, with one form
metastable under ordinary conditions, but stable under pressure (Barrio
et al., 2017b; Espeau et al., 2005; Ledru et al., 2007). Furthermore, the
solid-solid equilibrium line is also negative for paracetamol (Barrio et
al., 2017b; Espeau et al., 2005; Ledru et al., 2007). In more general
Fig. 6. Topological pressure-temperature phase diagram of spironolactone indicating the
relative positions of the stable phase regions of forms I and II, the vapor (V) and
the liquid (L). The liquid domain is shown in grey. Triple points: 1=II-L-V, 2=I-L-V,
3=I-II-L, 4=I-II-V. Two-phase equilibrium lines: aa=L-V, bb=I-V, cc=II-V, dd=II-L
and ee=I-L. Stability ranking of the two-phase equilibria (lines) and the triple points (cir-
cles): Black=stable, black and white=metastable, white=supermetastable.
terms, the phase diagram of spironolactone belongs to the third case
among the four possible cases of dimorphism described by
Bakhuis-Roozeboom (Bakhuis Roozeboom, 1901).
The experimental difficulties notwithstanding, spironolactone is in-
teresting due to the extremely rare difference of seventy degrees be-
tween the melting points of its two polymorphs as can be concluded
from the data compiled by Burger and Ramberger (Burger and
Ramberger, 1979b) and from more recently obtained data (Table 1). It
is unexpected that the lower melting polymorph actually possesses a sta-
ble domain in the pressure-temperature phase diagram, because it goes
against the rule of thumb that the densest form is also the most stable.
Taking into consideration the shallowness of the slopes of the two melt-
ing equilibria and the fact that they are very similar, one must conclude
that the Gibbs free energy surfaces of the two polymorphs are most
likely rather close to each other despite the large difference in melting
points. The closeness in Gibbs free energy can also be inferred from the
observation that form I shows little tendency to transform into form II
and thus that a strong driving force for this transition is lacking. This
is validated by the fact that both polymorphs do not contain hydrogen
bonds and thus that the main interactions involve only Van der Waals
forces and thus no strong energy barriers are expected that restrict phase
transformations.
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